Alto Neuroscience, Inc.
ANRO · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | -0.61 | -0.10 | 0.00 |
| FCF Yield | -47.56% | -6.09% | -3.99% | -1.88% |
| EV / EBITDA | 0.69 | -14.00 | -20.58 | -59.93 |
| Quality | ||||
| ROIC | -40.74% | -46.60% | -64.05% | -44.68% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 30.95% |
| Cash Conversion Ratio | 0.77 | 0.92 | 0.74 | 1.01 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | 594,292.20% |
| Free Cash Flow Growth | -45.94% | -60.55% | -112.49% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 2.20 | 2.10 | -1.23 | -1.38 |
| Interest Coverage | 49.90 | -27.60 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,148.08 | 0.00 | -1,714.01 | 1,519.16 |